As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.
While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
As the stream of executives flowing from large pharma companies to smaller biotechs builds into a torrent, another month has passed with a number of significant switches. Notably, two former Genentech employees, responsible for work on some of its bestselling...
Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.
Senior Scientist at Pfizer? Head of Upstream Development at GSK? How about working at B-MS’s expanding facility in Massachusetts? Time to dust off those CVs and check out the latest biopharma jobs.
Former Secretary of State and First Lady Hillary Clinton popped in for a long interview during one of the keynote luncheons to discuss all sorts of different topics with a BIO executive. The luncheon nicely complimented the international theme of the...
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
